Show simple item record

dc.contributor.authorRodriguez Gutierrez, D
dc.contributor.authorJones, C
dc.contributor.authorVarlet, P
dc.contributor.authorMackay, A
dc.contributor.authorWarren, D
dc.contributor.authorWarmuth-Metz, M
dc.contributor.authorSánchez Aliaga, E
dc.contributor.authorCalmon, R
dc.contributor.authorHargrave, DR
dc.contributor.authorCañete, A
dc.contributor.authorMassimino, M
dc.contributor.authorAzizi, AA
dc.contributor.authorLe Deley, M-C
dc.contributor.authorSaran, F
dc.contributor.authorRousseau, RF
dc.contributor.authorZahlmann, G
dc.contributor.authorGarcia, J
dc.contributor.authorVassal, G
dc.contributor.authorGrill, J
dc.contributor.authorMorgan, PS
dc.contributor.authorJaspan, T
dc.date.accessioned2020-04-03T10:24:11Z
dc.date.issued2020-01-10
dc.identifier.citationClinical cancer research : an official journal of the American Association for Cancer Research, 2020
dc.identifier.issn1078-0432
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/3581
dc.identifier.doi10.1158/1078-0432.ccr-19-3154
dc.description.abstractBACKGROUND:The HERBY trial evaluated the benefit of the addition of the antiangiogenic agent Bevacizumab (BEV) to radiotherapy/Temozolomide (RT/TMZ) in pediatric patients with newly diagnosed non-brainstem high-grade glioma (HGG). The work presented here aims to correlate imaging characteristics and outcome measures with pathological and molecular data. METHODS:Radiological, pathological and molecular data were correlated with trial clinical information to retrospectively re-evaluate event free and overall survival. RESULTS:One-hundred thirteen patients were randomized to the RT/TMZ arm (n =54) or the RT/TMZ+BEV (BEV arm; n =59). The tumor arose in the cerebral hemispheres in 68 patients (Cerebral group) and a midline location in 45 cases (Midline group). Pathological diagnosis was available in all cases and molecular data in 86/113. H3 K27M histone mutations were present in 23/32 Midline cases and H3 G34R/V mutations in 7/54 Cerebral cases. Total/near-total resection occurred in 44/68 (65%) Cerebral cases but only 5/45 (11%) Midline cases (p <0.05). Leptomeningeal metastases (27 cases, 13 with subependymal spread) at relapse were more frequent in Midline (17/45) than Cerebral tumors (10/68, p <0.05). Mean OS (14.1 months) and EFS (9.0 months) in Midline tumors were significantly lower than mean OS (20.7 months) and EFS (14.9 months) in Cerebral tumors (p <0.05). Pseudoprogression occurred in 8/111 (6.2%) cases. CONCLUSIONS:This study has shown that the poor outcome of midline tumors (compared to cerebral) may be related to 1) lesser surgical resection, 2) H3 K27M histone mutations, and 3) higher leptomeningeal dissemination.
dc.formatPrint-Electronic
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://www.rioxx.net/licenses/under-embargo-all-rights-reserved
dc.titleRadiological evaluation of newly diagnosed non-brainstem pediatric high-grade glioma in the HERBY phase II trial.
dc.typeJournal Article
dcterms.dateAccepted2020-01-07
rioxxterms.versionofrecord10.1158/1078-0432.ccr-19-3154
rioxxterms.licenseref.urihttps://www.rioxx.net/licenses/under-embargo-all-rights-reserved
rioxxterms.licenseref.startdate2020-01-10
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfClinical cancer research : an official journal of the American Association for Cancer Research
pubs.notes12 months
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Glioma Team
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Glioma Team
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Glioma Team
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Glioma Team
pubs.publication-statusPublished
pubs.embargo.terms12 months
icr.researchteamGlioma Teamen_US
dc.contributor.icrauthorJones, Chrisen
dc.contributor.icrauthorMackay, Alanen


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record